The approval of self-replicating mRNA vaccines: a dangerous precedent for health freedom

 The recent recommendation by the European Committee for Medicinal Products for Human Use (CHMP) to approve Kostaive, a self-replicating mRNA (saRNA) vaccine, marks a troubling escalation in the pharmaceutical industry’s push to deploy untested and potentially hazardous technologies on the global population. This decision, which now rests with the European Commission, raises serious concerns about the erosion of health freedom, government transparency, and the prioritization of corporate profits over public safety.

Self-replicating mRNA vaccines, such as Kostaive, are not merely another iteration of traditional mRNA technology. They represent a radical departure from conventional vaccines, introducing a mechanism that allows the injected mRNA to replicate within the body, akin to a viral infection. This “biological printing press” could theoretically amplify the vaccine’s presence and effects indefinitely, creating a cascade of unintended consequences that remain entirely unknown.

The clinical trial data for Kostaive is alarming, to say the least. Across phases 1, 2, and 3a, 90% of participants experienced adverse events after the first dose, with 74.5% reporting systemic reactions and 15.2% requiring medical attention. Five deaths were reported in the phase 3b study alone. These figures are not just statistics; they are human lives and health outcomes being sacrificed on the altar of expediency. Yet, despite these red flags, the CHMP has recommended approval, raising questions about the integrity of the regulatory process and the influence of pharmaceutical companies like Arcturus Therapeutics...<<<Read More>>>...

European Committee gives green light to use self-replicating vaccines on citizens of EU countries

 The Committee for Medicinal Products for Human Use has recommended marketing authorisation for Kostaive, a self-replicating mRNA (“saRNA”) injection developed by Arcturus Therapeutics. The final decision for regulatory approval now rests with the European Commission.

The European Commission must reject authorisation for these dangerous saRNA (replicon) vaccines.

On 12 December 2024, the European Committee for Medicinal Products for Human Use (“CHMP”) issued a positive opinion recommending marketing authorisation for Kostaive, a self-replicating (replicon) mRNA injection developed by Arcturus Therapeutics. The final decision for regulatory approval now rests with the European Commission:

Japan had already approved these injections last year. In November 2023, Japan’s Ministry of Health, Labor and Welfare (MHLW) fully approved CSL and Arcturus Therapeutics’ replicon shot, Kostaive ARCT-154. Despite enormous safety concerns, Japan’s MHLW approved the updated booster shot in September 2024 to target the JN.1 lineage of Omicron subvariants.

During the clinical trials for Kostaive, five deaths were reported among participants in the phase 3b study. Across study phases 1, 2, and 3a combined, 90% of injected participants experienced adverse events, with 74.5% reporting systemic reactions and 15.2% requiring medical attention after the first dose. Notably, many of the study authors are full-time employees of Arcturus Therapeutics, raising concerns about bias in their conclusions....<<<Read More>>>...

Arcturus Therapeutics is seeking approval from the FDA to go ahead with self-replicating bird flu vaccine trials

 On Monday, it was announced that Arcturus Therapeutics is actively seeking a green light from the FDA to begin Phase 1 trials for self-replicating “vaccines” against bird flu.

Except perhaps for the genetic code contained within them, these are the same injections that were rolled out last month in Japan and which the Japanese have been referring to as the “third atomic bomb” because the effects could be so devastating.

Self-amplifying RNA (“saRNA”), also termed self-replicating RNA (“srRNA”), and self-amplifying mRNA (“sa-mRNA” or “samRNA”) are synonymous terms. Both refer to a synthetic mRNA molecule engineered to replicate itself within host cells. Vaccines using this self-replicating technology are also called “replicon” vaccines.

In November 2023, Japan approved the use of the first saRNA vaccine against covid. The vaccine is called Kostaive and is also known as ARCT-154 or, in Vietnam, VBC-COV19-154. It is a CSL and Arcturus Therapeutics vaccine. At the time of the approval, researchers were hopeful that this was only the beginning for saRNA treatments for infectious diseases and even cancers. The vaccine, which the Japanese are referring to as the “third atomic bomb,” began to be rolled out in Japan in October 2024 as part of its autumn covid vaccination programme.

There is only explicit mention of Kostaive using STARR mRNA technology. However, it is likely that the Kostaive “vaccine” uses both of Arcturus Therapeutics’ proprietary technologies: STARR (self-transcribing and replicating RNA) mRNA technology and LUNAR (lipid-mediated universal RNA delivery) delivery system.

LUNAR is a nanoparticle delivery system that enables the efficient and targeted delivery of mRNA to cells. STARR is a self-replicating RNA platform that combines with LUNAR to drive “therapeutic” protein expression....<<<Read More>>>....

GLOBAL EMERGENCY UNFOLDING: Japan will unleash Bill Gates-approved, SELF-REPLICATING mRNA vaccines starting next month

More fearmongering to scare the gullible sleeping sheep.

 +++++++++++++++

 Bill Gate's diabolical plan to change vaccines is being expedited once more. After supporting lockdowns and vaccine mandates to capitalize on his global mRNA vaccine initiatives, he now wants the world population to take vaccines with "longer duration and greater coverage." This is the promise for a new class of "self-replicating" vaccines that are designed to amplify in people, all on their own.

By October 2024, Japan will become the first nation to introduce this controversial new type of COVID-19 vaccine called a self-replicating vaccine. The vaccine, known as Kostaive (ARCT-154), is a self-amplifying mRNA vaccine (saRNA) that replicates within the body, creating copies of foreign proteins and GENES for long-term encoding and long-term manipulation of antibody responses...<<<Read More>>>...